stockportfolio.pro
Axogen, Inc. (AXGN)
Healthcare · Medical Devices · NasdaqCM
Axogen, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.11M | $60.43M | $83.94M | $106.71M | $112.30M | $127.36M | $138.58M | $159.01M | $187.34M | $225.21M |
| Gross profit | $34.64M | $51.12M | $71.01M | $89.36M | $90.72M | $104.43M | $108.81M | $121.87M | $141.98M | $167.35M |
| Net income | $-14.41M | $-10.45M | $-22.40M | $-29.14M | $-23.79M | $-26.98M | $-28.95M | $-21.72M | $-9.96M | $-15.70M |
| Net margin | -35.1% | -17.3% | -26.7% | -27.3% | -21.2% | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% |
Source: Axogen, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of Axogen, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AXGN in your portfolio →
Axogen, Inc. financial history by metric
About Axogen, Inc.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Axogen, Inc. — frequently asked questions
What is Axogen, Inc.'s revenue?
Axogen, Inc. (AXGN) reported revenue of $225.21M for fiscal year 2025, up 20.2% from the prior year, according to its SEC filings.
Is Axogen, Inc. profitable?
No — AXGN reported a net loss of $-15.70M in fiscal 2025.
What is AXGN's P/E ratio?
Axogen, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Axogen, Inc. growing?
AXGN's revenue grew at roughly 14.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Axogen, Inc. have?
As of fiscal year 2025, AXGN carried roughly $48.39M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Axogen, Inc.'s gross margin?
AXGN's gross margin was 74.3% in fiscal 2025 — gross profit of $167.35M on revenue of $225.21M.
What is Axogen, Inc.'s market cap?
Axogen, Inc. (AXGN) has a market capitalization of about $2.23B, based on the latest data in our nightly-refreshed cache.
When does Axogen, Inc.'s fiscal year end?
AXGN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Axogen, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.